The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Immunome Inc shares valued at $46,900 were purchased by BIENAIME JEAN JACQUES on Jun 03 ’25. At $9.38 per share, BIENAIME JEAN JACQUES acquired 5,000 shares. The insider’s holdings grew to 36,415 shares worth approximately $0.39 million following the completion of this transaction.
Also, BIENAIME JEAN JACQUES purchased 7,800 shares, netting a total of over 60,684 in proceeds. Following the buying of shares at $7.78 each, the insider now holds 31,415 shares.
Before that, SIEGALL CLAY B had added 137,100 shares to its account. In a trade valued at $999,459, the President and CEO bought Immunome Inc shares for $7.29 each. Upon closing the transaction, the insider’s holdings increased to 137,100 shares, worth approximately $8.67 million.
As published in their initiating research note from Lake Street on April 02, 2025, Immunome Inc [IMNM] has been a Buy and the price target has been revised to $23. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in early November. As of May 31, 2024, Piper Sandler has initiated its “an Overweight” rating for IMNM. Earlier on April 30, 2024, JP Morgan initiated its rating. Their recommendation was “an Overweight” for IMNM stock.
Analyzing IMNM Stock Performance
On last trading session,, Immunome Inc [NASDAQ: IMNM] rose 1.42% to $10.75. The stock’s lowest price that day was $10.57, but it reached a high of $11.08 in the same session. During the last five days, there has been a drop of approximately -6.11%. Over the course of the year, Immunome Inc shares have dropped approximately -34.89%.
Support And Resistance Levels for Immunome Inc (IMNM)
RSI (Relative Strength Index) is 61.86 on the 14-day chart, showing neutral technical sentiment.
Is Immunome Inc subject to short interest?
Stocks of Immunome Inc saw a sharp rise in short interest on 2025-07-15 jumping by 1.68 million shares to 14.2 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 12.52 million shares. A jump of 11.82% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.58 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.58.
Which companies own the most shares of Immunome Inc (IMNM)?
In terms of Immunome Inc share price expectations, FactSet research, analysts set an average price target of 33 in the next 12 months, up nearly 211.32% from the previous closing price of $10.6. Analysts anticipate Immunome Inc stock to reach 35 by 2025, with the lowest price target being 23. In spite of this, 3 analysts ranked Immunome Inc stock as Buy at the end of 2025. On April 15, 2024, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $35.
